medigraphic.com
Instituto Nacional de Salud Pública

2018, Number 6

<< Back Next >>

salud publica mex 2018; 60 (6)

Use of HPV testing in cervical cancer screening services in Mexico, 2008-2018: a nationwide database study

Hurtado-Salgado E, Ortiz-Panozo E, Salmerón J, Saavedra-Lara N, Kuri-Morales P, Pesqueira-Villegas E, Luna-Gordillo R, Franco EL, Lazcano-Ponce E

Language: English
References: 40
Page: 722-733
PDF size: 921.55 Kb.


ABSTRACT

Objective. To describe the methods of a study aimed at evaluating high risk-HPV (hrHPV)-based screening and cervical cytology as triage compared to conventional cervical cytology as primary screening in the detection of grade 2+ cervical intraepithelial neoplasia in the National Cancer Screening Program (NCSP) of Mexico. Materials and methods. We will use information originated from the Womens Cancer Information System of Mexico regarding cervical cancer from 2008 to 2018. The database includes cytology results, diagnostic confirmation by histopathology and/or treatment colposcopy. We will then carry out statistical analyses on approximately 15 million hrHPV. Results. We will evaluate the overall performance of hrHPV-based screening as part of the NCSP and compare hrHPV-based to cytology-based screening under real-life conditions. To guarantee an unbiased comparison between hrHPV with cytology triage and conventional cytology we will use propensity score matching. Conclusion. Decision makers may use our results to identify areas of opportunity for improvement in NCSP processes.


REFERENCES

  1. Antoni S, Soerjomataram I, Møller B, Bray F, Ferlay J. An assessment of GLOBOCAN methods for deriving national estimates of cancer incidence. Bull World Health Organ. 2016;94(3):174-84. https://doi.org/10.2471/ BLT.15.164384

  2. Almonte M, Murillo R, Sánchez GI, Jerónimo J, Salmerón J, Ferrecio C, et al. Nuevos paradigmas y desafíos en la prevención y control del cáncer de cuello uterino en América Latina. Salud Publica Mex. 2010;52(6):544-59. https://doi.org/10.1590/S0036-36342010000600010

  3. Gómez-Dantés H, Lamadrid-Figueroa H, Cahuana-Hurtado L, Silverman- Retana O, Montero P, González-Robledo MC, et al. The burden of cancer in Mexico, 1990-2013. Salud Publica Mex. 2016;58(2):118-31. https://doi. org/10.21149/spm.v58i2.7780

  4. Palacio-Mejía LS, Lazcano-Ponce E, Allen-Leigh B, Hernández-Ávila M. Diferencias regionales en la mortalidad por cáncer de mama y cérvix en México entre 1979 y 2006. Salud Publica Mex. 2009;51:s208-19. https:// doi.org/10.1590/S0036-36342009000800011

  5. Instituto Nacional de Salud Pública. Evaluación del programa de Prevención y Control del Cáncer Cervical en México, 2008-2011. Problemas y Recomendaciones Cuernavaca: INSP, 2011 [cited 2017, Nov 14]. Available from: https://www.insp.mx/images/stories/Centros/cisp/Docs/120412_ cneg.pdf

  6. Bray F, Piñeros M. Cancer patterns, trends and projections in latin america and the caribbean: A global context. Salud Publica Mex. 2016;58(2):104- 17. https://doi.org/10.21149/spm.v58i2.7779

  7. Torres-Sánchez LE, Rojas-Martínez R, Escamilla-Núñez C, Vara-Salazar ED, Lazcano-Ponce E. Tendencias en la mortalidad por cáncer en México de 1980 a 2011. Salud Publica Mex. 2014;56(5):473-91. https://doi. org/10.21149/spm.v56i5.7373

  8. Lazcano-Ponce E, Palacio-Mejia LS, Allen-Leigh B, Yunes-Diaz E, Alonso P, Schiavon R, Hernandez-Avila M. Decreasing cervical cancer mortality in Mexico: effect of Papanicolaou coverage, birthrate, and the importance of diagnostic validity of cytology. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2808-17. https://doi.org/10.1158/1055-9965.EPI-07-2659

  9. Torres-Mejía G, Ortega-Olvera C, Ángeles-Llerenas A, Villalobos-Hernández AL, Salmerón-Castro J, Lazcano-Ponce E, Hernández-Ávila M. Patrones de utilización de programas de prevención y diagnóstico temprano de cáncer en la mujer. Salud Publica Mex. 2013;55(Suppl 2):241-8. https:// doi.org/10.21149/spm.v55s2.5121

  10. Ronco G, Zappa M, Franceschi S, Tunesi S, Caprioglio A, Confortini M. Impact of variations in triage cytology interpretation on human papillomavirus- based cervical screening and implications for screening algorithms. Eur J Cancer. 2016;68:148-55. https://doi.org/10.1016/j.ejca.2016.09.008

  11. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103(5):368-83. https://doi.org/10.1093/jnci/djq562

  12. Lazcano-Ponce E, Lörincz AT, Salmerón J, Fernández I, Cruz A, Hernández P, et al. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican social security program. Cancer Causes Control. 2010;21(10):1693-700. https://doi.org/10.1007/s10552- 010-9598-2

  13. Flores YN, Bishai DM, Lorincz A, Shah KV, Lazcano-Ponce E, Hernández M, et al. HPV testing for cervical cancer screening appears more costeffective than Papanicolau cytology in Mexico. Cancer Causes Control. 2011;22(2):261-72. https://doi.org/10.1007/s10552-010-9694-3

  14. Ronco G, Dillner J, Elfstrom M, Tunesi S, Snijders P, Arbyn M. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2013;383(13):524- 32. https://doi.org/10.1016/S0140-6736(13)62218-7

  15. Leinonen MK, Nieminen P, Lönnberg S, Malila N, Hakama M, Pokhrel A, et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: Prospective randomised trial in Finland. BMJ. 2012;345(7886):1-11. https://doi.org/10.1136/bmj.e7789

  16. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. Can Med Assoc J. 2001:1017-25.

  17. Franco EL. A New generation of studies of human papillomavirus DNA testing in cervical cancer screening. JNCI J Natl Cancer Inst. 2009;101(23):1600-01. https://doi.org/10.1093/jnci/djp392

  18. Reynoso-Noverón N, Meneses-García A, Erazo-Valle A, Escuderode los Ríos P, Kuri-Morales PA, Mohar-Betancourt A. Challenges in the development and implementation of the National Comprehensive Cancer Control Program in Mexico. Salud Publica Mex. 2016;58(2):325-33. https:// doi.org/10.21149/spm.v58i2.7804

  19. Guadarrama F. Prevención y Control del Cáncer de la Mujer. Ciudad de México: Centro Nacional de Equidad de Género y Salud Reproductiva, 2013 [cited 2017, Nov 15]. Available from: http://cnegsr.salud.gob. mx/contenidos/descargas/cama/PrevencionyControldelCancerdelaMujer_ 2013_2018.pdf

  20. Secretaría de Salud. Modificación a la Norma Oficial Mexicana NOM- 014-SSA2-1994, para la Prevención Tratamiento y Control, del Cáncer del Cuello del Útero y Mamario en la atención primaria, para quedar como, NOM-014-SSA2-1994, Para la Prevención, Detección, Diagnóstico, Trata. México: DOF, 1993 [cited 2017, Nov 14]. Available from: http://www.salud. gob.mx/unidades/cdi/nom/m014ssa24.html

  21. Comisión Nacional contra las Adicciones. Programa Sectorial de Salud. México: Conadic [cited 2018, Jun 15]. Available from: http://www.conadic. salud.gob.mx/pdfs/sectorial_salud.pdf

  22. Bärnighausen T, Røttingen JA, Rockers P, Shemilt I, Tugwell P. Quasiexperimental study designs series—paper 1: introduction: two historical lineages. J Clin Epidemiol. 2017;89:4-11. https://doi.org/10.1016/j. jclinepi.2017.02.020

  23. Geldsetzer P, Fawzi W. Quasi-experimental study designs series–paper 2: complementary approaches to advancing global health knowledge. J Clin Epidemiol. 2017;89:12-6. https://doi.org/10.1016/j.jclinepi.2017.03.015

  24. Frenk J, Gómez-Dantés O. Quasi-experimental study designs series–paper 3: systematic generation of evidence through public policy evaluation. J Clin Epidemiol. 2017;89:17-20. https://doi.org/10.1016/j. jclinepi.2017.03.013

  25. Bärnighausen T, Tugwell P, Røttingen JA, Shemilt I, Rockers P, Geldsetzer P, et al. Quasi-experimental study designs series–paper 4: uses and value. J Clin Epidemiol. 2017;89:21-29. https://doi.org/10.1016/j. jclinepi.2017.03.012

  26. Torres-Ibarra L, Lazcano-Ponce E, Franco EL, Shemilt I, Rockers P, Geldsetzer P, et al. Triage strategies in cervical cancer detection in Mexico: Methods of the FRIDA study. Salud Publica Mex. 2016;58(2):197-210. https:// doi.org/10.21149/spm.v58i2.7789

  27. Salmerón J, Torres-Ibarra L, Bosch FX, Cuzick J, Lörincz A, Wheeler CM, et al. HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico TT - Impacto de la vacunación de VPH en un programa de tamizaje de cáncer cervical: métodos del Estudio FASTER-Tlalpan en México. Salud Publica Mex. 2016;58(2):211-9. https://doi.org/10.21149/spm.v58i2.7790

  28. Tejada RA, Vargas KG, Benites-zapata V, Mezones-Holguín E, Bolaños- Díaz R, Hernandez AV. Human papillomavirus vaccine efficacy in the prevention of anogenital warts: systematic review and meta-analysis. Salud Publica Mex. 2017;59(1):84-94. https://doi.org/10.21149/7824

  29. Wentzensen N, Walker JL, Gold MA, Smith KM, Zuna RE, Mathews C, et al. Multiple Biopsies and Detection of Cervical Cancer Precursors at Colposcopy. J Clin Oncol. 2014;33(1):83-9. https://doi.org/10.1200/ JCO.2014.55.9948

  30. James H. Nelson, Hervy E. Averette RMR. Dysplasia, carcinoma in situ, and early invasive cervical carcinoma. Cancer J Clin. 1984;34(6):306-27. https://doi.org/10.3322/canjclin.34.6.306

  31. Consejo Nacional de Población. Indices de marginación por entidad federativa y municipio. Índices De Marginación. México: Conapo, 2010:73-189.

  32. Consejo Nacional de Población. Índices de Marginación. México: Conapo, 2012 [cited 2017, Nov 19]. Available from: http://www.conapo.gob.mx/ es/CONAPO/Indices_de_Marginacion

  33. Instituto Nacional de Estadística y Geografía. Regiones socioeconómicas de México. México: Inegi, 2000 [cited 2018, Jan 31]. Available from: http://www3.inegi.org.mx/sistemas/cntmp/itaeegranjero.aspx

  34. Harvey G. Multilevel Statistical Models. London nstitute Educ Multilevel Model Proj. London: Institute of Education, Multilevel Models, 1999.

  35. Pepe MS. Oxford Statistical Science. New York: Oxford University Press Inc, 2003.

  36. Whiting P, Rutjes AWS, Reitsma JB, Glas AS, Bossuyt PMM, Kleijnen J. Sources of Variation and Bias in Studies of Diagnostic Accuracy. Ann Intern Med. 2004;140(3):189. https://doi.org/10.7326/0003-4819-140-3- 200402030-00010

  37. Delgado-Rodríguez M, Llorca J. Bias. J Epidemiol Community Health. 2004;58(8):635-41. https://doi.org/10.1136/jech.2003.008466

  38. Lijmer JG. Empirical Evidence of Design-Related Bias. JAMA. 1999;282(11):1061-6. https://doi.org/10.1001/jama.282.11.1061

  39. Schmidt RL, Walker BS, Cohen MB. Verification and classification bias interactions in diagnostic test accuracy studies for fine-needle aspiration biopsy. Cancer Cytopathol. 2015;123(3):193-201. https://doi.org/10.1002/ cncy.21503

  40. Begg CB, Greenes RA. Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics. 1983;39:207-15. https://doi.org/10.2307/2530820




2020     |     www.medigraphic.com